Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response

<i>Background and Objectives</i>: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in asse...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oana Irina Gavril, Lidia Iuliana Arhire, Otilia Gavrilescu, Mihaela Dranga, Oana Barboi, Radu Sebastian Gavril, Roxana Popescu, Cristina Cijevschi Prelipcean, Anca-Victorita Trifan, Catalina Mihai
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	chronic hepatitis C virus patatin-like phospholipase domain-containing3 direct acting antiviral sustained viral response Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/688afb938113409696156dd118f48f7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:688afb938113409696156dd118f48f7f
record_format	dspace
spelling	oai:doaj.org-article:688afb938113409696156dd118f48f7f2021-11-25T18:18:08ZRole of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response10.3390/medicina571111531648-91441010-660Xhttps://doaj.org/article/688afb938113409696156dd118f48f7f2021-10-01T00:00:00Zhttps://www.mdpi.com/1648-9144/57/11/1153https://doaj.org/toc/1010-660Xhttps://doaj.org/toc/1648-9144<i>Background and Objectives</i>: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in assessing evolution, prognosis and monitoring of hepatic disease, especially after treatment with direct-acting antivirals (DAAs). The aim of this study was to assess the link between patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism and the degree of hepatic steatosis and fibrosis in patients with chronic HCV infection, as well as changes in steatosis and fibrosis three monthsafter obtaining a sustained viral response (SVR). <i>Materials and Methods</i>:Ourstudy included 100 patients with chronic hepatitis C (CHC) infection and compensated cirrhosis who received DAA treatment and who were evaluated using Fibromax prior to and 3 months after SVR. The influence of PNPLA3 (CC, CG, GG) genotype among these patients on the degree of post-treatment regression of steatosis and fibrosis was assessed. <i>Results</i>: Regression was noticed in the degree of both hepatic steatosis and hepatic fibrosis post-DAA treatment (three months after SVR). Analysis of the correlation between PNPLA3 genotype and fibrosis indicated that the average level of fibrosis (F) before DAA treatment was higher in patients with the GG genotype than in patients with the CC or CG genotype. Three months after SVR, the average level of fibrosis decreased; however, it remained significantly increased in GG subjects compared to that in CC or CG patients. The degree of hepatic steatosis before treatment was not significantly different among patients with different PNPLA3 genotypes, and no significant correlations were observed three months after SVR. <i>Conclusions</i>: The genetic variants of PNPLA3 influence the evolution of hepatic fibrosis. The GG subtype plays an important role in the degree of hepatic fibrosis both before and after treatment (three months after SVR)and could be a prognostic marker for assessment of post-SVR evolution.Oana Irina GavrilLidia Iuliana ArhireOtilia GavrilescuMihaela DrangaOana BarboiRadu Sebastian GavrilRoxana PopescuCristina Cijevschi PrelipceanAnca-Victorita TrifanCatalina MihaiMDPI AGarticlechronic hepatitis C viruspatatin-like phospholipase domain-containing3direct acting antiviralsustained viral responseMedicine (General)R5-920ENMedicina, Vol 57, Iss 1153, p 1153 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic hepatitis C virus patatin-like phospholipase domain-containing3 direct acting antiviral sustained viral response Medicine (General) R5-920
spellingShingle	chronic hepatitis C virus patatin-like phospholipase domain-containing3 direct acting antiviral sustained viral response Medicine (General) R5-920 Oana Irina Gavril Lidia Iuliana Arhire Otilia Gavrilescu Mihaela Dranga Oana Barboi Radu Sebastian Gavril Roxana Popescu Cristina Cijevschi Prelipcean Anca-Victorita Trifan Catalina Mihai Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
description	<i>Background and Objectives</i>: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in assessing evolution, prognosis and monitoring of hepatic disease, especially after treatment with direct-acting antivirals (DAAs). The aim of this study was to assess the link between patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism and the degree of hepatic steatosis and fibrosis in patients with chronic HCV infection, as well as changes in steatosis and fibrosis three monthsafter obtaining a sustained viral response (SVR). <i>Materials and Methods</i>:Ourstudy included 100 patients with chronic hepatitis C (CHC) infection and compensated cirrhosis who received DAA treatment and who were evaluated using Fibromax prior to and 3 months after SVR. The influence of PNPLA3 (CC, CG, GG) genotype among these patients on the degree of post-treatment regression of steatosis and fibrosis was assessed. <i>Results</i>: Regression was noticed in the degree of both hepatic steatosis and hepatic fibrosis post-DAA treatment (three months after SVR). Analysis of the correlation between PNPLA3 genotype and fibrosis indicated that the average level of fibrosis (F) before DAA treatment was higher in patients with the GG genotype than in patients with the CC or CG genotype. Three months after SVR, the average level of fibrosis decreased; however, it remained significantly increased in GG subjects compared to that in CC or CG patients. The degree of hepatic steatosis before treatment was not significantly different among patients with different PNPLA3 genotypes, and no significant correlations were observed three months after SVR. <i>Conclusions</i>: The genetic variants of PNPLA3 influence the evolution of hepatic fibrosis. The GG subtype plays an important role in the degree of hepatic fibrosis both before and after treatment (three months after SVR)and could be a prognostic marker for assessment of post-SVR evolution.
format	article
author	Oana Irina Gavril Lidia Iuliana Arhire Otilia Gavrilescu Mihaela Dranga Oana Barboi Radu Sebastian Gavril Roxana Popescu Cristina Cijevschi Prelipcean Anca-Victorita Trifan Catalina Mihai
author_facet	Oana Irina Gavril Lidia Iuliana Arhire Otilia Gavrilescu Mihaela Dranga Oana Barboi Radu Sebastian Gavril Roxana Popescu Cristina Cijevschi Prelipcean Anca-Victorita Trifan Catalina Mihai
author_sort	Oana Irina Gavril
title	Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
title_short	Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
title_full	Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
title_fullStr	Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
title_full_unstemmed	Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
title_sort	role of pnpla3 in the assessment and monitoring of hepatic steatosis and fibrosis in patients with chronic hepatitis c infection who achieved a sustained virologic response
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/688afb938113409696156dd118f48f7f
work_keys_str_mv	AT oanairinagavril roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT lidiaiulianaarhire roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT otiliagavrilescu roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT mihaeladranga roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT oanabarboi roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT radusebastiangavril roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT roxanapopescu roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT cristinacijevschiprelipcean roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT ancavictoritatrifan roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse AT catalinamihai roleofpnpla3intheassessmentandmonitoringofhepaticsteatosisandfibrosisinpatientswithchronichepatitiscinfectionwhoachievedasustainedvirologicresponse
_version_	1718411386126598144

Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response

Ejemplares similares